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SUMMARY – The aim of the study was to determine the incidence, risk factors and efficiency of 
the neutrophil gelatinase-associated lipocalin (NGAL) biomarker in early diagnosis of acute kidney 
injury (AKI) in newborns. The study was designed as a prospective, clinical, epidemiological investiga-
tion conducted in the period of three years, which included 50 newborns with AKI hospitalized in the 
Neonatal Intensive Care Unit, University Children’s Hospital in Skopje. The estimated prevalence of 
AKI was 6.4%, while the prevalence according to RIFLE classification was 8.7%. Perinatal asphyxia 
was a common predisposing factor associated to kidney injury. The mortality rate was 32% and was 
significantly higher in the group of newborns with congenital heart diseases. There was a significant 
difference between NGAL values and creatinine values on the day of admission. There was a signifi-
cant difference in NGAL values between newborns with AKI and lethal outcome and newborns 
without lethal outcome (p<0.001). In conclusion, AKI is a life-threatening condition. It is an indepen-
dent contributor to mortality. Urinary NGAL is an early predictive biomarker of AKI in critically ill 
newborns.
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Introduction
Acute kidney injury (AKI) is a common clinical 
problem in newborns in the Neonatal Intensive Care 
Unit (NICU). It is a sudden, often reversible decrease 
in kidney function that results in deterioration of kid-
ney ability to excrete urine in sufficient quantity and 
adequate composition, rendering it unable to maintain 
normal homeostasis of body fluids and electrolytes1-5.
Because of immaturity, neonatal kidney is particu-
larly sensitive to reduction of kidney function. Neona-
tal glomerular filtration rate (GFR) is 25% compared 
to adults, so any reduction in kidney function leads to 
kidney damage. The incidence of AKI in the neonatal 
population is 8% to 24%, and the mortality rate ranges 
up to 35%6-9.
The predisposing factors associated with neonatal 
kidney injury are certain clinical conditions such as 
perinatal asphyxia, neonatal sepsis, prematurity, meco-
nium aspiration syndrome, congenital heart diseases, 
therapeutic interventions and other nephrotoxic drugs. 
Appropriate treatment of associated comorbidities 
and reduction in the use of potential nephrotoxic drugs 
reduce the risk of AKI in neonates in NICU10-14.
Because of the need of timely and appropriate di-
agnostics and assessment of the severity of kidney in-
jury, RIFLE classification is used in neonates with 
AKI. Liborio et al.15 made adaptation to the neonatal 
RIFLE classification, in which the corrected values of 
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serum creatinine and 24-hour urine output are taken 
as criteria. This classification includes three levels that 
classify the severity of disease (risk, damage and insuf-
ficiency) and two levels which classify the outcome of 
kidney injury17-21.
So far, the diagnosis of kidney injury has been 
based on the determination of serum creatinine, which 
is the most commonly used parameter for GFR. How-
ever, its use in the neonatal period is significantly lim-
ited. Namely, during the first 2 to 3 days of life, serum 
creatinine reflects the function of the maternal kid-
neys, showing higher values that subsequently decrease 
in the following days. On the other hand, the level of 
serum creatinine may change and increase, even after 
48-72 hours of the initial kidney injury. Therefore, se-
rum creatinine is considered as a late functional mark-
er of kidney injury22.
Renal biomarkers can detect kidney injury in the 
first 2 to 3 hours of its occurrence, even before there is 
a decrease in diuresis and an increase in serum creati-
nine. Several renal biomarkers are described in the lit-
erature such as cystatin C, interleukin 18 (IL-18) and 
neutrophil gelatinase-associated lipocalin (NGAL)23,24.
In our study, we used NGAL, a small (25 kDa) gly-
coprotein from the family of lipoclins that is a com-
pound of 178 amino acids and is found in specific 
granules in neutrophils. It is a protease-resistant poly-
peptide that is freely filtered through the glomeruli, is 
reabsorbed into the proximal tubule and eventually 
secreted by the urine. Its values largely reflect damage 
to endothelial cells of the tubules, but not reduction of 
glomerular filtration. The serum and urinary NGAL 
concentrations correlate with the severity of the dis-
ease, indicating the degree of current kidney injury. 
Therefore, NGAL represents the most promising bio-
marker for early detection of AKI. Its use allows us to 
make the right clinical decisions at the right time, be-
fore the illness is clinically manifest, and take appro-
priate measures to prevent renal function decline25.
The aim of the study was to determine the inci-
dence, risk factors and efficiency of the NGAL bio-
marker in early diagnosis of neonatal AKI.
Patients and Methods
The study was designed as a prospective, clinical, 
epidemiological investigation conducted in the period 
of three years, which included 50 newborns with AKI 
hospitalized in NICU, University Children’s Hospital 
in Skopje.
The criteria for inclusion in the study were infants 
up to 28 days of postnatal age; infants treated in NICU 
due to certain pathological condition, development of 
kidney injury, AKI defined by elevated serum creati-
nine (>130 mmol/L in infants younger than 33 weeks 
and >90 mmol/L in infants older than 33 weeks), and 
presence of oliguria (less than 1.0 mL/kg/h). Accord-
ing to our criteria, all infants older than 28 days of age 
with less than 24 hours of hospitalization and infants 
having undergone cardiac surgery interventions were 
excluded from the study.
Data from medical records of the admitted neo-
nates with AKI were analyzed. The neonates were ana-
lyzed according to gender, birth weight, gestational age 
and comorbid conditions such as sepsis, asphyxia, pre-
maturity, meconium aspiration syndrome, and con-
genital heart diseases that were associated with AKI. 
All the newborns included in the study were classified 
according to the neonatal RIFLE classification crite-
ria. Laboratory examinations of serum creatinine val-
ues were performed by use of a Kodak camera dry bio-
chemistry at the Laboratory of Biochemistry, Univer-
sity Children’s Hospital.
In this study, the NGAL biomarker was applied for 
the first time at our institution. It was analyzed in 
urine samples collected with urinary sachet or urinary 
catheter. In the investigated group of patients (infants 
with documented acute renal impairment), urine was 
collected on two occasions (day 0 as day of receipt and 
day 3 of receipt). Urine samples were frozen at -70 to 
-80 °C and were transferred to the Department of 
Biochemistry
The concentration of NGAL in urine specimens 
was determined in duplicate, in the Department of 
biochemistry, by using NGAL ELISA method (Bio-
porto, Hellerup, Denmark). The assay is a sandwich 
ELISA performed in microwells coated with a nomo-
clonal antibody to human NGAL.
The material was statistically analyzed using the 
methods of descriptive statistics. To determine the sig-
nificance of differences in the parameters, the tests for 
independent samples were used. The level of statistical 
significance was set at p<0.05.
This study was conducted during preparation of the 
PhD thesis (S.N.T) and was approved by the Ethics 
Committee of the Skopje Medical School. Informed 
consent was obtained from the newborn parents.
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Results
Of the total of 770 patients hospitalized at the 
NICU, University Children’s Hospital in the period of 
three years (2014-2016), 50 infants with documented 
AKI were evaluated in the study. According to gender 
distribution, male infants predominated (n=34/50; 
68%) over female ones (n=16/50; 32%). The male to 
female ratio was 2.1:1. Most of the neonates involved 
in the study were born at term (n=31; 62%), whereas 
19 (38%) were born prematurely. Demographic char-
acteristics of the study newborns are shown in Table 1.
Table 2 shows the prevalence and distribution of 
predisposing factors associated with AKI among the 
neonates. Perinatal asphyxia was the most common 
predisposing factor observed in 15 (30%) newborns, 
with male predominance (Fig. 1). Other predisposing 
factors were neonatal sepsis and prematurity with re-
spiratory distress syndrome observed in 12 (24%) neo-
nates, congenital heart diseases in six (12%) and meco-
nium aspiration syndrome in five (10%) neonates.
The mortality among hospitalized newborns with 
AKI was 32%. It was significantly higher in the group 
of patients with congenital heart diseases than in the 
others (p=0.01). Distribution of mortality according to 
predisposing factors associated with AKI is illustrated 
in Figure 2.
Table 1. Demographic characteristics of hospitalized 




























Table 2. Predisposing factors for acute kidney injury  
in newborns




Congenital heart disease 6 12
Prematurity with respiratory 
distress syndrome 12 24
Sepsis 12 24
Fig. 1. Predisposing factors for acute kidney injury according to gender.
MAS = meconium aspiration syndrome
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Fig. 2. Distribution of mortality according to predisposing factors associated with acute kidney 
injury.
MAS = meconium aspiration syndrome
Fig. 3. Distribution of serum creatinine in newborns 
with acute kidney injury.
Fig. 4. Neutrophil gelatinase-associated lipocalin 
(NGAL) monitoring on the day of hospitalization and 
three days later.
Fig. 5. Distribution of serum creatinine and urinary 
NGAL in newborns with acute kidney injury.
Cr = creatinine; NGAL = neutrophil gelatinase-associated lipocalin
Table 3. Distribution of serum creatinine and urinary 
NGAL in newborns with acute kidney injury




















NGAL = neutrophil gelatinase-associated lipocalin
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The mean serum creatinine level in newborns with 
AKI was 76.78±30.6 mmol/L on the day of admission 
to the NICU and 184.44±103.74 mmol/L after 72 
hours. In the next days, serum creatinine showed a de-
creasing trend. Distribution of serum creatinine levels 
in newborns with AKI is shown in Figure 3.
Study results showed higher values of urinary 
NGAL in newborns with AKI on the day of admis-
sion (373.8±194.9) and a slight upward trend, with 
further increase on the third day after admission 
(439.4±254.7; p<0.001) (Fig. 4).
Distribution of creatinine and NGAL values 
among the neonates in shown in Table 3 and Figure 5. 
There was a significant difference between NGAL val-
ues and serum values on the day of admission to the 
NICU.
There was a significant difference in the values of 
urinary NGAL between newborns with AKI and le-
thal outcome and newborns without lethal outcome 
(p<0.001). The mean urinary NGAL values in neo-
nates with AKI with lethal outcome was 586.39±182.3 
versus 254.22±28.5 in neonates without lethal out-
come (Fig. 6).
neonates was 6.3%, whereas in the study by Bolat et 
al.27 it was 8.0%. However, there are opposite findings. 
Thus, Momtaz et al.28 report on the incidence of AKI 
of 1.5%, Mortazavi et al.29 on 2.7%, and Agras et al.30 
on 3.4%. We assume that these differences can be due 
to differences in the criteria for diagnosing kidney in-
jury in newborns31. In our study, the prevalence of neo-
natal AKI according to RIFLE classification was 8.7%, 
indicating that in the present study, the diagnosis of 
AKI must have been missed in the majority of neo-
nates according to the standard classification. It is as-
sumed that the therapy administered for other indica-
tions probably led to the resolution of kidney injury. 
This finding indicates that RIFLE classification can be 
used as a more sensitive method than the standard 
classification in the diagnosis and monitoring of kid-
ney injury in neonates at NICU32.
The most common associated predisposing factor 
was perinatal asphyxia observed in 30% of newborns, 
with a predominance of term male newborns born 
with a low Apgar score in the fifth minute of life. This 
finding correlates with the data reported from the 
study by Abu-Haweleh33, according to which 42% of 
AKI patients had perinatal asphyxia as a dominant 
contributing condition.
In our study, mortality rate was 32%, which is con-
sistent with the data reported by Kapoor et al.34. It was 
significantly higher in newborns with congenital heart 
disease and secondary development of sepsis, where 
invasive therapeutic procedures such as intubation and 
assisted ventilation were applied35.
In this study, NGAL was first applied as an early 
biomarker of AKI in newborns. Before the use of 
 biomarker, the diagnosis of kidney injury was based 
on determination of serum creatinine. In our study, 
we found an increase in serum creatinine 72 hours 
 after hospitalization of newborns at the NICU. This 
finding shows that by measuring serum creatinine, the 
disease can be detected when clear clinical signs and 
symptoms are already present. This confirms that 
 serum creatinine is a late functional marker of kidney 
injury.
In our study, we detected significantly higher values 
of urinary NGAL on the day of admission of critically 
ill newborns at the NICU compared to creatinine val-
ues. This finding indicates that NGAL is a sensitive 
marker in the diagnosis of kidney injury. These data 
correlate with the data reported by Nickolas et al.36 and 
Fig. 6. Values of urinary NGAL in newborns with AKI 
and lethal outcome compared to newborns without lethal 
outcome.
NGAL = neutrophil gelatinase-associated lipocalin; AKI = acute 
kidney injury
Discussion
The estimated prevalence of AKI in neonates ac-
cording to the standard definition was 6.4%, which is 
consistent with literature data. A similar finding has 
been reported from the study conducted by Vach-
vanichsanong et al.26, where the incidence of AKI in 
Silvana Naunova-Timovska et al. NGAL as a biomarker for AKI in newborns
60 Acta Clin Croat, Vol. 59, No. 1, 2020
Youssef et al.37, emphasizing the role of NGAL as a 
sensitive marker in detecting kidney injury.
Follow-up of urinary NGAL on the day of hospi-
talization of newborns at the NICU and three days 
later showed a growing trend of the average value. The 
finding of significantly higher NGAL values on initial 
measurement suggested that renal damage had proba-
bly occurred before hospitalization of newborns at the 
NICU. Namely, all critically ill newborns from the ter-
ritory of the Republic of Macedonia are referred to our 
department, which is the only specialized tertiary cen-
ter for intensive therapy. This explains the presence of 
kidney injury when admitting critically ill newborns in 
whom AKI has not yet been clinically manifested. On 
the other hand, the high values of urinary NGAL re-
corded on admission to the NICU confirm the role 
of NGAL as an early marker of kidney injury. Mishra 
et al.38 and Devarajan39 in their studies also point to the 
ability of NGAL to early detect the newborns at risk 
of AKI.
The values of NGAL in newborns with AKI and 
lethal outcomes were significantly higher than in new-
borns without lethal outcome. This finding suggests 
that the level of urinary NGAL significantly correlates 
with the severity and outcome of the disease, indicat-
ing the extent of current kidney injury. Zappitelli et 
al.40 report similar results of significantly higher 
NGAL values in critically ill children with AKI and 
lethal outcomes.
The findings in our study confirm the applicability 
of the NGAL biomarker in the early diagnosis of AKI 
in newborns.
Conclusion
Acute kidney injury is a serious life-threatening 
condition, especially in the neonatal period. It is an in-
dependent contributor to mortality. In this study, 
NGAL as an early biomarker of AKI was used for the 
first time in our environment. NGAL provides an ear-
ly diagnosis of kidney injury in the first hours of its 
occurrence, when the disease is not yet clinically man-
ifested. That is why we propose its wider application as 
an early marker for the diagnosis of AKI in sick infants 
with different clinical conditions hospitalized at the 
NICU.
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Sažetak
LIPOKALIN UDRUŽEN S NEUTROFILNOM GELATINAZOM KAO RANI BIOLOŠKI BILJEG  
AKUTNOG OŠTEĆENJA BUBREGA U NOVOROĐENČADI
S. Naunova-Timovska, S. Cekovska, E. Sahpazova i V. Tasić
Cilj istraživanja bio je utvrditi incidenciju, čimbenike rizika i učinkovitost biološkog biljega lipokalina udruženog s neu-
trofilnom gelatinazom (neutrophil gelatinase-associated lipocalin, NGAL) u ranoj dijagnostici akutnog oštećenja bubrega 
(AOB) kod novorođenčadi. Istraživanje je provedeno kao prospektivna klinička epidemiološka studija kroz razdoblje od tri 
godine, a obuhvatila je 50 novorođenčadi s AOB hospitalizirane u Neonatalnoj jedinici intenzivnog liječenja (NJIL) Sveuči-
lišne dječje bolnice u Skopju. Procijenjena učestalost AOB bila je 6,4%, dok je učestalost prema klasifikaciji RIFLE iznosila 
8,7%. Perinatalna asfiksija bila je čest predisponirajući čimbenik udružen s oštećenjem bubrega. Stopa smrtnosti bila je 32% 
i bila je značajno viša u skupini novorođenčadi s kongenitalnim srčanim bolestima. Utvrđena je značajna razlika među vri-
jednostima NGAL i kreatinina na dan prijma u NJIL. Značajna razlika zabilježena je u vrijednostima NGAL između novo-
rođenčadi s AOB i smrtnim ishodom i novorođenčadi bez smrtnog ishoda (p<0,001). U zaključku, AOB je za život opasno 
stanje koje neovisno doprinosi smrtnosti. NGAL u mokraći je rani predskazujući biološki biljeg za AOB kod kritično bole-
sne novorođenčadi.
Ključne riječi: Rizični čimbenici; Rana dijagnostika; Akutno oštećenje bubrega; Novorođenče; Biomarkeri; Lipokalin-2
